Skip to main content
. 2019 Jun 13;3(12):1799–1807. doi: 10.1182/bloodadvances.2018028761

Table 2.

Treatment exposure and reasons for discontinuation in integrated safety analysis

Ibrutinib (N = 330)
Treatment exposure
 Exposure, median (range), mo 29.0 (0.2-42.9)
Duration of treatment, mo
 ≤6 32 (10)
 >6 to 12 18 (5)
 >12 to 24 34 (10)
 >24 to 36 193 (58)
 >36 53 (16)
Treatment discontinuation 124 (38)
 PD 52 (16)
 AE 37 (11)
 Death 18 (5)
 Physician decision 9 (3)
 Withdrawal by patient 8 (2)

Unless otherwise noted, all data are n (%).